Intrepid Financial Planning Group’s Sarepta Therapeutics SRPT Stock Holding History

Intrepid Financial Planning Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,075	Closed	-$252K	–	125
2024 Q4	$252K	Hold	2,075	–	–	0.11%	104
2024 Q3	$259K	Hold	2,075	–	–	0.11%	104
2024 Q2	$328K	Hold	2,075	–	–	0.14%	91
2024 Q1	$269K	Buy	+2,075	New	+$254K	0.12%	105
2023 Q4	–	Sell	-2,050	Closed	-$249K	–	126
2023 Q3	$249K	Hold	2,050	–	–	0.13%	97
2023 Q2	$235K	Hold	2,050	–	–	0.11%	101
2023 Q1	$283K	Hold	2,050	–	–	0.14%	89
2022 Q4	$266K	Hold	2,050	–	–	0.14%	88
2022 Q3	$227K	Buy	+2,050	New	+$207K	0.13%	88

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Intrepid Financial Planning Group's SRPT Position: Q1 2025 in Review

Intrepid Financial Planning Group sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,075 shares — an estimated $252K sold.

Intrepid Financial Planning Group first reported a position in SRPT in Q3 2022 and held it in 9 quarters. The position peaked at $328K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Intrepid Financial Planning Group reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Intrepid Financial Planning Group sold 2,075 Sarepta Therapeutics shares in Q1 2025, an estimated $252K.
Intrepid Financial Planning Group first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 9 quarters.
Intrepid Financial Planning Group's Sarepta Therapeutics position peaked at $328K in Q2 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Intrepid Financial Planning Group's 13F filing for Q1 2025, filed 13 May 2025.